Submission systemSubmit
Advanced Search
Volume 5 Issue 4
Oct.  2025
Turn off MathJax
Article Contents
Article Navigation >  Frigid Zone Medicine  > 2025  >  5(4): 231-241
Xin Wang, Xuyao Ji, Siyao Zhang, Benzhi Cai, Yu Liu. LncRNA-TUG1 as a potential diagnostic biomarker for coronary atherosclerotic heart disease[J]. Frigid Zone Medicine, 2025, 5(4): 231-241. doi: 10.1515/fzm-2025-0025
Citation: Xin Wang, Xuyao Ji, Siyao Zhang, Benzhi Cai, Yu Liu. LncRNA-TUG1 as a potential diagnostic biomarker for coronary atherosclerotic heart disease[J]. Frigid Zone Medicine, 2025, 5(4): 231-241. doi: 10.1515/fzm-2025-0025
shu

LncRNA-TUG1 as a potential diagnostic biomarker for coronary atherosclerotic heart disease

doi: 10.1515/fzm-2025-0025
  • 1.

    Department of Pharmacy at The Second Affiliated Hospital, and Department of Pharmacology at College of Pharmacy (the Key Laboratory of Cardiovascular Medicine Research, Ministry of Education); Institute of Clinical Pharmacy, the Heilongjiang Key Laboratory of Drug Research, Harbin Medical University, Harbin 150000, China

  • 2.

    Department of Laboratory medicine, Fourth Affiliated Hospital of Harbin Medical University, Harbin 150001, China

Funds:

the China Postdoctoral Science Foundation 2018T110318

the Innovation and Entrepreneurship Training Program for College Students S202110226047

More Information
    Abstract
  •   Objectives  Accumulating evidence suggests that people living in cold regions have a higher risk of developing coronary atherosclerotic heart disease (CHD). Long non-coding RNAs (lncRNAs) have been implicated in the pathogenesis and treatment of a variety of diseases. The present study aimed to investigate the serum level of lncRNA-taurine upregulated gene 1 (TUG1) in patients with CHD and assess its potential as a diagnostic biomarker. This study aimes to investigate the serum level of lncRNA-TUG1 in patients with CHD and assess its potential as a diagnostic biomarker.  Methods  The Gene Expression Omnibus (GEO) database was employed to identify the potential lncRNAs serving as biomarkers for CHD. To validate lncRNA-TUG1, 232 subjects were enrolled in both test and diagnostic cohorts. Serum lncRNA-TUG1 levels were measured by RT-qPCR. The association between lncRNA-TUG1 levels and CHD severity was analyzed using Pearson's correlation test. Diagnostic value was assessed by receiver operating characteristic (ROC) curve analysis and compared with established cardiac biomarkers.  Results  LncRNA-TUG1 was identified in the GEO database as a potential biomarker for CHD. Serum lncRNA-TUG1 levels were significantly higher in CHD patients compared with healthy controls and non-CHD patients. CRP levels also differed between CHD and non-CHD groups, while other biomarkers showed no significant differences. ROC curve analysis demonstrated that lncRNA-TUG1 could distinguish CHD from non-CHD patients, with an area under the curve (AUC) of 0.8916, which was higher than that of conventional biomarkers such as cTnI. At a cut-off value of 2.311, the sensitivity and specificity of lncRNA-TUG1 were 61.63% and 97.67%, respectively, surpassing the diagnostic performance of cTnI. Furthermore, lncRNA-TUG1 levels in CHD patients were positively correlated with SYNTAX scores from coronary angiography and increased with the severity of vascular stenosis.  Conclusion  Elevated serum lncRNA-TUG1 levels in CHD patients suggest that lncRNA-TUG1 may serve as a novel and valuable diagnostic biomarker for CHD, with potential utility in differentiating CHD from other cardiac diseases.

     

    • FullText(HTML)
  • loading
    • References(30)
  • [1]
    Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet, 2012; 380(9859): 2095-2128. doi: 10.1016/S0140-6736(12)61728-0
    [2]
    Khera A V, Emdin C A, Drake I, et al. Genetic risk, adherence to a healthy lifestyle, and coronary disease. N Engl J Med, 2016; 375(24): 2349-2358. doi: 10.1056/NEJMoa1605086
    [3]
    Huang Y. The novel regulatory role of lncRNA-miRNA-mRNA axis in cardiovascular diseases. J Cell Mol Med, 2018; 22(12): 5768-5775. doi: 10.1111/jcmm.13866
    [4]
    Liao J, Wang J, Liu Y, et al. Transcriptome sequencing of lncRNA, miRNA, mRNA and interaction network constructing in coronary heart disease. BMC Med Genomics, 2019; 12(1): 124. doi: 10.1186/s12920-019-0570-z
    [5]
    Schmitz S U, Grote P, Herrmann B G. Mechanisms of long noncoding RNA function in development and disease. Cell Mol Life Sci, 2016; 73(13): 2491-2509. doi: 10.1007/s00018-016-2174-5
    [6]
    Sun J, Hu J, Wang G, et al. LncRNA TUG1 promoted KIAA1199 expression via miR-600 to accelerate cell metastasis and epithelial-mesenchymal transition in colorectal cancer. J Exp Clin Cancer Res, 2018; 37(1): 106. doi: 10.1186/s13046-018-0771-x
    [7]
    Han Y, Liu C, Lei M, et al. LncRNA TUG1 was upregulated in osteoporosis and regulates the proliferation and apoptosis of osteoclasts. J Orthop Surg Res, 2019; 14(1): 416. doi: 10.1186/s13018-019-1430-4
    [8]
    Qiu N, Xu X, He Y. LncRNA TUG1 alleviates sepsis-induced acute lung injury by targeting miR-34b-5p/GAB1. BMC Pulm Med, 2020; 20(1): 49. doi: 10.1186/s12890-020-1084-3
    [9]
    Du H, Yang L, Zhang H, et al. LncRNA TUG1 silencing enhances proliferation and migration of ox-LDL-treated human umbilical vein endothelial cells and promotes atherosclerotic vascular injury repairing via the Runx2/ANPEP axis. Int J Cardiol, 2021; 338: 204-214. doi: 10.1016/j.ijcard.2021.05.014
    [10]
    Su Q, Liu Y, Lv X W, et al. Inhibition of lncRNA TUG1 upregulates miR-142-3p to ameliorate myocardial injury during ischemia and reperfusion via targeting HMGB1- and Rac1-induced autophagy. J Mol Cell Cardiol, 2019; 133: 12-25. doi: 10.1016/j.yjmcc.2019.05.021
    [11]
    Su Y, Sun Y, Tang Y, et al. Circulating miR-19b-3p as a novel prognostic biomarker for acute heart failure. J Am Heart Assoc, 2021; 10(20): e022304. doi: 10.1161/JAHA.121.022304
    [12]
    Scanlon P J, Faxon D P, Audet A M, et al. ACC/AHA guidelines for coronary angiography: Executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Coronary Angiography) developed in collaboration with the Society for Cardiac Angiography and Interventions. Circulation, 1999; 99(17): 2345-2357. doi: 10.1161/01.CIR.99.17.2345
    [13]
    Malhotra R K, Indrayan A. A simple nomogram for sample size for estimating sensitivity and specificity of medical tests. Indian J Ophthalmol, 2010; 58(6): 519-522. doi: 10.4103/0301-4738.71699
    [14]
    Lih O S, Jahmunah V, San T R, et al. Comprehensive electrocardiographic diagnosis based on deep learning. Artif Intell Med, 2020; 103: 101789. doi: 10.1016/j.artmed.2019.101789
    [15]
    Ghadrdoost B, Haghjoo M, Firouzi A. Accuracy of cardiogoniometry compared with electrocardiography in the diagnosis of coronary artery disease. Res Cardiovasc Med, 2015; 4(1): e25547. doi: 10.5812/cardiovascmed.25547
    [16]
    Kim H M, Kim H L, Kim M A et al. Additional roles of diastolic parameters in the diagnosis of obstructive coronary artery disease. Coron Artery Dis, 2021; 32(2): 145-151. doi: 10.1097/MCA.0000000000000970
    [17]
    Arbab-Zadeh A, Di Carli M F, Cerci R, et al. Accuracy of computed tomographic angiography and single-photon emission computed tomography-acquired myocardial perfusion imaging for the diagnosis of coronary artery disease. Circ Cardiovasc Imaging, 2015; 8(10): e003533. doi: 10.1161/CIRCIMAGING.115.003533
    [18]
    Li H, Sun K, Zhao R, et al. Inflammatory biomarkers of coronary heart disease. Front Biosci (Schol Ed), 2018; 10: 185-196. doi: 10.2741/s508
    [19]
    Nair M, Sandhu S S, Sharma A K. Cancer molecular markers: A guide to cancer detection and management. Semin Cancer Biol, 2018; 52(Pt 1): 39-55. doi: 10.1016/j.semcancer.2018.02.002
    [20]
    Vegter E L, Van der Meer P, De Windt L J, et al. MicroRNAs in heart failure: From biomarker to target for therapy. Eur J Heart Fail, 2016; 18(5): 457-468. doi: 10.1002/ejhf.495
    [21]
    Meng S, Zhou H, Feng Z, et al. CircRNA: Functions and properties of a novel potential biomarker for cancer. Mol Cancer, 2017; 16(1): 94. doi: 10.1186/s12943-017-0663-2
    [22]
    Beermann J, Piccoli M T, Viereck J, et al. Non-coding RNAs in development and disease: Background, mechanisms, and therapeutic approaches. Physiol Rev, 2016; 96(4): 1297-1325. doi: 10.1152/physrev.00041.2015
    [23]
    Guo F, Tang C, Li Y et al. The interplay of LncRNA ANRIL and miR-181b on the inflammation-relevant coronary artery disease through mediating NF-kappaB signalling pathway. J Cell Mol Med, 2018; 22(10): 5062-5075. doi: 10.1111/jcmm.13790
    [24]
    Zhu Y, Yang T, Duan J et al. MALAT1/miR-15b-5p/MAPK1 mediates endothelial progenitor cells autophagy and affects coronary atherosclerotic heart disease via mTOR signaling pathway. Aging (Albany NY), 2019; 11(4): 1089-1109. doi: 10.18632/aging.101766
    [25]
    Xiong G, Jiang X, Song T. The overexpression of lncRNA H19 as a diagnostic marker for coronary artery disease. Rev Assoc Med Bras (1992), 2019; 65(2): 110-117. doi: 10.1590/1806-9282.65.2.110
    [26]
    Du H, Yang L, Zhang H, et al. LncRNA TUG1 silencing enhances proliferation and migration of ox-LDL-treated human umbilical vein endothelial cells and promotes atherosclerotic vascular injury repairing via the Runx2/ANPEP axis. Int J Cardiol, 2021; 338: 204-214. doi: 10.1016/j.ijcard.2021.05.014
    [27]
    Tang Y, Hu J, Zhong Z, et al. Long noncoding RNA TUG1 promotes the function in ox-LDL-Treated HA-VSMCs via miR-141-3p/ROR2 axis. Cardiovasc Ther, 2020; 2020: 6758934. doi: 10.1155/2020/6758934
    [28]
    Yang L, Li T. LncRNA TUG1 regulates ApoM to promote atherosclerosis progression through miR-92a/FXR1 axis. J Cell Mol Med, 2020; 24(15): 8836-8848. doi: 10.1111/jcmm.15521
    [29]
    Fu D, Gao T, Liu M, et al. LncRNA TUG1 aggravates cardiomyocyte apoptosis and myocardial ischemia/reperfusion injury. Histol Histopathol, 2021; 36(12): 1261-1272.
    [30]
    You G, Long X, Song F, et al. Metformin activates the AMPK-mTOR pathway by modulating lncRNA TUG1 to induce autophagy and inhibit atherosclerosis. Drug Des Devel Ther, 2020; 14: 457-468. doi: 10.2147/DDDT.S233932
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(7)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (11) PDF downloads(0) Cited by()
    Proportional views
    Related

    Contact Us

    Editorial Office: Frigid Zone Medicine, Editorial Office of Frigid Zone Medicine, Heilongjiang Health Development Research Center, Zhongshan Road 112, Xiangfang District, Harbin, 150036, China

    Tel: 0451-87253028

    E-mail: editorialoffice@frigidzonemedicine.com

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    Links

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return